Acro Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 21, 2022 at 03:42 pm
Share
Acro Biomedical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 4.01 million compared to USD 2.99 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.05 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to USD 0.05 a year ago.
For the nine months, sales was USD 0.2985 million compared to USD 0.5995 million a year ago. Net loss was USD 11.94 million compared to USD 3.85 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.07 a year ago. Diluted loss per share from continuing operations was USD 0.2 compared to USD 0.07 a year ago.
Acro Biomedical Co., Ltd. is principally engaged in the business is the sale of cordyceps related products. The Company is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The Company's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus, which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The Company is involved in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. It sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.
ACRO BIOMEDICAL CO., LTD. 